BI 10773 and Glimepiride Interaction Study

Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau up to 5 days, Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval tau up to 5 days and 2 more. Started Apr 2009; status: completed.